Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Quest Diagnostics (DGX) Tops Q1 EPS by 18c, Beats on Revenue; Offers FY24 Guidance
April 23, 2024 6:47 AM EDTQuest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.04, $0.18 better than the analyst estimate of $1.86. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.29 billion.
GUIDANCE:
Quest Diagnostics sees FY2024 EPS of $8.72-$8.97, versus the consensus of $8.75.... More
